Substance / Medication

Avapritinib

Overview

Active Ingredient
avapritinib
RxNorm CUI
2272107
Labeler: Blueprint Medicines CorporationUpdated: 2025-07-11T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis.
Pilkington Hollie, Smith Sarah, Roskell Neil et al. · Future Oncol · 2022
PMID: 35114819Meta-Analysis
Avapritinib versus Placebo in Indolent Systemic Mastocytosis.
Gotlib Jason, Castells Mariana, Elberink Hanneke Oude et al. · NEJM Evid · 2023
PMID: 38320129RCT
Evaluation of the effectiveness and safety of avapritinib in real-world Spanish cases with gastrointestinal stromal tumor and D842V-PDGFRA mutation.
Nuñez Hernández Isaac, Gómez Palmero Cristina, Delgado Juan Ramón et al. · Oncologist · 2025
PMID: 40349140ObservationalFull text (PMC)
Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control study.
Reiter Andreas, Gotlib Jason, Álvarez-Twose Iván et al. · Leuk Res · 2025
PMID: 40712393Observational
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis.
Reiter Andreas, Gotlib Jason, Álvarez-Twose Iván et al. · Leukemia · 2022
PMID: 35790816ObservationalFull text (PMC)
CRE25-047: Avapritinib Induced Pseudoprogression in a Gastrointestinal Stromal Tumor With a PDGFRA Exam 18 842 Mutation.
Trivedi Charmi, Murtha Timothy, Zaidi Zane et al. · J Natl Compr Canc Netw · 2025
PMID: 40154328Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Avapritinib (substance)
SNOMED CT
838462005
UMLS CUI
C4743552
RxNorm CUI
2272107
Labeler
Blueprint Medicines Corporation

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.